FLT3 and acute myeloid leukemia: To verify whether these immune and stromal cell-relevant DEGs identified from TCGA AML patients are also associated with mutations in an independent AML cohort, we analyzed the gene expression levels of 524 AML cases from GSE14468, for which FLT3-ITD, NPM1 and biCEBPA mutation data were available.